Atria Wealth Solutions Inc. Raises Holdings in Bristol-Myers Squibb (NYSE:BMY)

Atria Wealth Solutions Inc. boosted its stake in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 12.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 190,678 shares of the biopharmaceutical company's stock after buying an additional 21,516 shares during the period. Atria Wealth Solutions Inc.'s holdings in Bristol-Myers Squibb were worth $10,785,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. AMF Tjanstepension AB increased its holdings in shares of Bristol-Myers Squibb by 6.9% in the 3rd quarter. AMF Tjanstepension AB now owns 610,181 shares of the biopharmaceutical company's stock worth $31,618,000 after purchasing an additional 39,419 shares in the last quarter. Swedbank AB lifted its holdings in shares of Bristol-Myers Squibb by 0.9% during the 3rd quarter. Swedbank AB now owns 3,139,552 shares of the biopharmaceutical company's stock valued at $162,440,000 after buying an additional 28,427 shares during the period. Cyndeo Wealth Partners LLC boosted its stake in shares of Bristol-Myers Squibb by 3.9% in the 3rd quarter. Cyndeo Wealth Partners LLC now owns 9,535 shares of the biopharmaceutical company's stock worth $493,000 after buying an additional 357 shares during the last quarter. Vest Financial LLC bought a new stake in shares of Bristol-Myers Squibb in the third quarter worth $438,000. Finally, Raleigh Capital Management Inc. increased its position in Bristol-Myers Squibb by 42.7% during the third quarter. Raleigh Capital Management Inc. now owns 42,480 shares of the biopharmaceutical company's stock valued at $2,198,000 after acquiring an additional 12,705 shares during the last quarter. Hedge funds and other institutional investors own 76.41% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have issued reports on BMY. Daiwa America raised Bristol-Myers Squibb from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, November 13th. Morgan Stanley raised their price objective on shares of Bristol-Myers Squibb from $36.00 to $39.00 and gave the stock an "underweight" rating in a report on Tuesday, November 12th. Jefferies Financial Group raised Bristol-Myers Squibb from a "hold" rating to a "buy" rating and raised their price objective for the stock from $63.00 to $70.00 in a research note on Monday, December 16th. Truist Financial boosted their price objective on Bristol-Myers Squibb from $62.00 to $65.00 and gave the company a "buy" rating in a research note on Wednesday, January 8th. Finally, Citigroup raised their price objective on shares of Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a "neutral" rating in a research report on Tuesday, January 28th. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating, four have assigned a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, Bristol-Myers Squibb has an average rating of "Hold" and an average target price of $57.86.

Insider Activity at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Samit Hirawat purchased 1,823 shares of the firm's stock in a transaction that occurred on Friday, February 14th. The stock was purchased at an average cost of $54.84 per share, with a total value of $99,973.32. Following the purchase, the executive vice president now owns 63,932 shares of the company's stock, valued at approximately $3,506,030.88. The trade was a 2.94 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.09% of the stock is currently owned by insiders.

Bristol-Myers Squibb Price Performance

Bristol-Myers Squibb stock traded up $0.06 during mid-day trading on Friday, reaching $55.85. 11,100,311 shares of the company's stock traded hands, compared to its average volume of 10,886,042. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $61.10. The company has a quick ratio of 1.15, a current ratio of 1.25 and a debt-to-equity ratio of 2.90. The stock has a 50 day moving average of $56.99 and a two-hundred day moving average of $54.24. The company has a market cap of $113.33 billion, a price-to-earnings ratio of -12.63, a PEG ratio of 2.04 and a beta of 0.45.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 EPS for the quarter, beating analysts' consensus estimates of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. Equities analysts forecast that Bristol-Myers Squibb will post 6.74 earnings per share for the current year.

Bristol-Myers Squibb Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, February 3rd. Stockholders of record on Friday, January 3rd were given a dividend of $0.62 per share. The ex-dividend date was Friday, January 3rd. This represents a $2.48 annualized dividend and a dividend yield of 4.44%. This is an increase from Bristol-Myers Squibb's previous quarterly dividend of $0.60. Bristol-Myers Squibb's payout ratio is currently -56.11%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.